431 related articles for article (PubMed ID: 9179544)
1. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.
Akanji AO; Abdullah A; Tahzeeb S
Eur J Clin Invest; 1997 May; 27(5):380-6. PubMed ID: 9179544
[TBL] [Abstract][Full Text] [Related]
2. The relationships between insulin and plasminogen activator inhibitor 1 levels: assessment in groups of subjects with dyslipidaemia and hypertension.
Akanji AO; Al-Shayji I
Clin Chim Acta; 1998 Jun; 274(1):41-52. PubMed ID: 9681596
[TBL] [Abstract][Full Text] [Related]
3. Determinants of blood levels of some thrombogenic biomarkers in healthy Arab adolescent subjects.
Akanji AO; Al-Isa AN; Thalib L
Clin Chem Lab Med; 2011 Oct; 49(10):1681-90. PubMed ID: 21663566
[TBL] [Abstract][Full Text] [Related]
4. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
Zitoun D; Bara L; Basdevant A; Samama MM
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):77-81. PubMed ID: 8548430
[TBL] [Abstract][Full Text] [Related]
5. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Gürlek A; Bayraktar M; Kirazli S
Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
[TBL] [Abstract][Full Text] [Related]
6. The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea.
Park YS; Park S; Park KS; Kim SY; Lee HK; Koh CS; Min HK; Kim JQ
Diabetes Res Clin Pract; 1994 May; 24(1):25-31. PubMed ID: 7924883
[TBL] [Abstract][Full Text] [Related]
7. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
8. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction.
Thøgersen AM; Söderberg S; Jansson JH; Dahlén G; Boman K; Nilsson TK; Lindahl B; Weinehall L; Stenlund H; Lundberg V; Johnson O; Ahrén B; Hallmans G
Eur J Cardiovasc Prev Rehabil; 2004 Feb; 11(1):33-40. PubMed ID: 15167204
[TBL] [Abstract][Full Text] [Related]
9. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.
De Pergola G; De Mitrio V; Sciaraffia M; Pannacciulli N; Minenna A; Giorgino F; Petronelli M; Laudadio E; Giorgino R
Metabolism; 1997 Nov; 46(11):1287-93. PubMed ID: 9361687
[TBL] [Abstract][Full Text] [Related]
10. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S
Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238
[TBL] [Abstract][Full Text] [Related]
11. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
[TBL] [Abstract][Full Text] [Related]
13. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications.
Testa R; Bonfigli AR; Sirolla C; De Grazia G; Compagnucci P; Manfrini S; Fumelli D; Testa I
Diabetes Nutr Metab; 2000 Oct; 13(5):269-75. PubMed ID: 11105969
[TBL] [Abstract][Full Text] [Related]
14. [Relationship of age, sex, body weight, smoking, blood lipids and fibrinolytic activities in healthy subjects].
Xiong X; Wang Z; Zhao S
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(1):65-7. PubMed ID: 11938745
[TBL] [Abstract][Full Text] [Related]
15. Hemostatic variables, carbohydrate metabolism and lipid profile in women with low body mass index.
Polac I; Stachowiak G; Jedrzejczyk S; Stetkiewics T; Sobieszczanska S; Pertynski T
Gynecol Endocrinol; 2003 Apr; 17(2):151-7. PubMed ID: 12744226
[TBL] [Abstract][Full Text] [Related]
16. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
Hadigan C; Meigs JB; Rabe J; D'Agostino RB; Wilson PW; Lipinska I; Tofler GH; Grinspoon SS;
J Clin Endocrinol Metab; 2001 Feb; 86(2):939-43. PubMed ID: 11158071
[TBL] [Abstract][Full Text] [Related]
17. Inheritance conjointly contributing to fibrinolysis and hyperlipidemia.
Glueck CJ; Glueck HI; Tracy T; Speirs J; Stroop D
Metabolism; 1993 Nov; 42(11):1410-9. PubMed ID: 8231835
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
19. [Relationship of lipoprotein(a) to fibrinolytic activities in healthy subjects].
Xiong X; Zhao S; Wang Z; Lo L; Huang Q
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):555-7. PubMed ID: 10806767
[TBL] [Abstract][Full Text] [Related]
20. Determinants of glycated LDL levels in nondiabetic and diabetic hyperlipidaemic patients in Kuwait.
Akanji AO; Abdella N; Mojiminiyi OA
Clin Chim Acta; 2002 Mar; 317(1-2):171-6. PubMed ID: 11814472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
